Hugo Akabane, MD

Dr. Hugo Akabane is an expert at studying how to customize treatments for patients battling acute leukemias. His work enhances patient outcomes while mitigating the adverse effects of treatments. His consistent record of achievement, as seen through his valuable peer-reviewed publications, work products, and leadership roles, certify his influence in the field.

Dr. Akabane’s research contributions have helped improve the safety of drug treatments administered to patients with serious medical conditions such as acute leukemia, non-Hodgkin's lymphoma, and severe aplastic anemia. More specifically, they have informed the medical community that CY-BU treatments pose less risk than BU-CY treatments. Armed with this information, doctors are able to better select the most optimal treatment for patients that undergo hematopoietic stem cell transplantation.

Lastly, Dr. Akabane has continually disseminated the output of his studies, amassing an impressive publication record. With his work featured in journals including the Journal of Clinical Oncology, the Journal of the American Society of Nephrology, and Clinical Lymphoma Myeloma and Leukemia, Dr. Akabane is a respected contributor within his field.